Vitalhub Corp. (TSE:VHI - Free Report) - Equities researchers at Raymond James dropped their FY2025 EPS estimates for Vitalhub in a note issued to investors on Sunday, May 11th. Raymond James analyst M. Freeman now forecasts that the company will post earnings per share of $0.17 for the year, down from their previous estimate of $0.23. Raymond James has a "Moderate Buy" rating on the stock. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. Raymond James also issued estimates for Vitalhub's Q4 2025 earnings at $0.05 EPS, Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.28 EPS.
A number of other brokerages have also commented on VHI. Canaccord Genuity Group increased their price objective on Vitalhub from C$12.00 to C$12.50 and gave the company a "buy" rating in a report on Thursday, January 16th. TD Securities raised their target price on Vitalhub from C$13.00 to C$14.00 and gave the company a "buy" rating in a report on Monday, March 31st. Finally, Scotiabank set a C$14.00 target price on shares of Vitalhub and gave the stock an "outperform" rating in a research report on Thursday, January 30th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of C$12.90.
Get Our Latest Analysis on VHI
Vitalhub Stock Performance
VHI stock opened at C$10.68 on Wednesday. The firm has a market cap of C$577.71 million, a PE ratio of 173.71, a PEG ratio of 1.18 and a beta of 1.26. Vitalhub has a 1 year low of C$6.50 and a 1 year high of C$12.34. The company has a fifty day simple moving average of C$9.96 and a 200 day simple moving average of C$10.64.
Vitalhub Company Profile
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
